Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at StockNews.com

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a research note issued to investors on Monday. Other equities analysts also recently issued reports about the company. Canaccord Genuity Group cut their target price on Rocket Pharmaceuticals from $49.00 to $47.00 and set a “buy” rating on the […]

Related Keywords

Gaurav Shah ,Stifel Nicolaus ,Needham Company ,Analyst Recommendations For Rocket Pharmaceuticals ,Insider Transactions At Rocket Pharmaceuticals ,Clearstead Advisors ,Advisor Group Holdings Inc ,Rocket Pharmaceuticals Stock Down ,Rocket Pharmaceuticals ,News Ratings For Rocket Pharmaceuticals Daily ,Rocket Pharmaceuticals Inc ,Life Insurance Co ,Wells Fargo Company ,Steward Partners Investment Advisory ,Securities Exchange Commission ,Canaccord Genuity Group ,Get Free Report ,Genuity Group ,Chardan Capital ,Pharmaceuticals Stock Down ,Exchange Commission ,Group Holdings ,Partners Investment Advisory ,Metropolitan Life Insurance ,Life Insurance ,Rocket Pharmaceuticals Daily ,Nasdaq Rckt ,Rckt ,Medical ,Upgrade ,Stocknews Com ,